Invasive hepatocellular carcinoma without any isolated tumor 
Disease needing 2 injections of Therasphere 
Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis 
Previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization 
No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib 
Associated disease which could prevent patient from receiving treatment 
RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or contrast product contre-indication (allergy) 
Patient already participating in an other therapeutic trial with an experimental drug 
Pregnant or childbearing potential women or breastfeeding women 
minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons 
Unable to sign an informed consent       
    

NCT02003339_exc_T1
Condition
hepatocellular carcinoma
NCT02003339_exc_T2
Qualifier
Invasive
NCT02003339_exc_T3
Condition
isolated tumor
NCT02003339_exc_T4
Negation
without
NCT02003339_exc_T6
Condition
Thrombosis
NCT02003339_exc_T7
Qualifier
extending into the porta
NCT02003339_exc_T8
Condition
thrombosis
NCT02003339_exc_T9
Qualifier
left branch
NCT02003339_exc_T10
Qualifier
right branch
NCT02003339_exc_T11
Scope
left or right branch
NCT02003339_exc_T13
Negation
authorized
NCT02003339_exc_T14
Condition
extra hepatic metastasis
NCT02003339_exc_T15
Procedure
chemoembolization
NCT02003339_exc_T16
Procedure
radiofrequency
NCT02003339_exc_T17
Temporal
less than 3 months before radioembolization
NCT02003339_exc_T18
Reference_point
radioembolization
NCT02003339_exc_T19
Scope
chemoembolization, radiofrequency
NCT02003339_exc_T20
Temporal
15 days before radioembolization
NCT02003339_exc_T21
Temporal
15 days after radioembolization
NCT02003339_exc_T22
Negation
No
NCT02003339_exc_T23
Procedure
antiangiogenic treatment
NCT02003339_exc_T24
Drug
Sorafenib
NCT02003339_exc_T25
Condition
Associated disease
NCT02003339_exc_T26
Qualifier
could prevent patient from receiving treatment
NCT02003339_exc_T28
Procedure
RMI
NCT02003339_exc_T29
Condition
RMI contre-indication
NCT02003339_exc_T32
Condition
Pregnant
NCT02003339_exc_T33
Condition
childbearing potential
NCT02003339_exc_T34
Person
women
NCT02003339_exc_T35
Observation
breastfeeding
NCT02003339_exc_T36
Person
women
NCT02003339_exc_T38
Person
minors